Literature DB >> 11543672

[2',6'-Dimethyltyrosine]dynorphin A(1-11)-NH2 analogues lacking an N-terminal amino group: potent and selective kappa opioid antagonists.

Y Lu1, T M Nguyen, G Weltrowska, I Berezowska, C Lemieux, N N Chung, P W Schiller.   

Abstract

Recent studies showed that dermorphin and enkephalin analogues containing two methyl groups at the 2',6'-positions of the Tyr(1) aromatic ring and lacking an N-terminal amino group were moderately potent delta and mu opioid antagonists. These results indicate that a positively charged N-terminal amino group may be essential for signal transduction but not for receptor binding and suggested that its deletion in agonist opioid peptides containing an N-terminal 2',6'-dimethyltyrosine (Dmt) residue may represent a general way to convert them into antagonists. In an attempt to develop dynorphin A (Dyn A)-derived kappa opioid antagonists, we prepared analogues of [Dmt(1)]Dyn A(1-11)-NH2 (1), in which the N-terminal amino group was either omitted or replaced with a methyl group. This was achieved by replacement of Tyr(1) with 3-(2,6-dimethyl-4-hydroxyphenyl)propanoic acid (Dhp) or (2S)-2-methyl-3-(2,6-dimethyl-4-hydroxyphenyl)propanoic acid [(2S)-Mdp]. Compounds were tested in the guinea pig ileum and mouse vas deferens bioassays and in rat and guinea pig brain membrane receptor binding assays. All analogues turned out to be potent kappa antagonists against Dyn A(1-13) and the non-peptide agonist U50,488 and showed only weak mu and delta antagonist activity. The most potent and most selective kappa antagonist of the series was [(2S)-Mdp(1)]Dyn A(1-11)-NH2 (5, dynantin), which showed subnanomolar kappa antagonist potency against Dyn A(1-13) and very high kappa selectivity both in terms of its K(e) values determined against kappa, mu, and delta agonists and in terms of its ratios of kappa, mu, and delta receptor binding affinity constants. Dynantin is the first potent and selective Dyn A-derived kappa antagonist known and may complement the non-peptide kappa antagonists norbinaltorphimine and GNTI as a pharmacological tool in opioid research.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11543672     DOI: 10.1021/jm0101186

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  19 in total

Review 1.  Dynorphin A analogs for the treatment of chronic neuropathic pain.

Authors:  Sara M Hall; Yeon Sun Lee; Victor J Hruby
Journal:  Future Med Chem       Date:  2016-01-29       Impact factor: 3.808

2.  Novel opioid peptide derived antagonists containing (2S)-2-methyl-3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid [(2S)-Mdcp].

Authors:  Animesh Ghosh; Jie Luo; Chen Liu; Grazyna Weltrowska; Carole Lemieux; Nga N Chung; Yixin Lu; Peter W Schiller
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

3.  Novel opioid cyclic tetrapeptides: Trp isomers of CJ-15,208 exhibit distinct opioid receptor agonism and short-acting κ opioid receptor antagonism.

Authors:  Nicolette C Ross; Kate J Reilley; Thomas F Murray; Jane V Aldrich; Jay P McLaughlin
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

4.  'Carba'-carfentanil (trans isomer): a μ opioid receptor (MOR) partial agonist with a distinct binding mode.

Authors:  Grazyna Weltrowska; Carole Lemieux; Nga N Chung; Jason J Guo; Brian C Wilkes; Peter W Schiller
Journal:  Bioorg Med Chem       Date:  2014-07-29       Impact factor: 3.641

5.  "Carba"-analogues of fentanyl are opioid receptor agonists.

Authors:  Grazyna Weltrowska; Nga N Chung; Carole Lemieux; Jianxin Guo; Yixin Lu; Brian C Wilkes; Peter W Schiller
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

6.  Unexpected opioid activity profiles of analogues of the novel peptide kappa opioid receptor ligand CJ-15,208.

Authors:  Jane V Aldrich; Santosh S Kulkarni; Sanjeewa N Senadheera; Nicolette C Ross; Kate J Reilley; Shainnel O Eans; Michelle L Ganno; Thomas F Murray; Jay P McLaughlin
Journal:  ChemMedChem       Date:  2011-07-14       Impact factor: 3.466

7.  N-methylated cyclic enkephalin analogues retain high opioid receptor binding affinity.

Authors:  Grazyna Weltrowska; Irena Berezowska; Carole Lemieux; Nga N Chung; Brian C Wilkes; Peter W Schiller
Journal:  Chem Biol Drug Des       Date:  2009-12-17       Impact factor: 2.817

8.  Deletion of Ac-NMePhe(1) from [NMePhe(1) ]arodyn under acidic conditions, part 2: effects of substitutions on pharmacological activity.

Authors:  Wei-Jie Fang; Marco A Bennett; Thomas F Murray; Jane V Aldrich
Journal:  Biopolymers       Date:  2011       Impact factor: 2.505

9.  Cyclic opioid peptide agonists and antagonists obtained via ring-closing metathesis.

Authors:  Irena Berezowska; Carole Lemieux; Nga N Chung; Brian C Wilkes; Peter W Schiller
Journal:  Chem Biol Drug Des       Date:  2009-08-20       Impact factor: 2.817

10.  Stereoselective synthesis of (3S)- and (3R)-3-hydroxy-3-(2,6-dimethyl-4-hydroxyphenyl)propanoic acid and its incorporation into a cyclic enkephalin analogue.

Authors:  Grazyna Weltrowska; Carole Lemieux; Nga N Chung; Brian C Wilkes; Peter W Schiller
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.